Preclinical pharmacokinetics of CASC-578, a novel, selective, potent, and orally bioavailable small molecule checkpoint kinase 1 inhibitor

SOL578Poster
Written By James Cotton
James Cotton
Previous

Modulating Protein-Protein Interactions of the Mitotic Polo-like Kinases to Target Mutant KRAS
Next

The novel orally available sub-nanomolar potent and selective checkpoint kinase 1 inhibitor CASC-578 is highly active in mantle cell lymphoma as a single agent and in combination with Wee1 inhibition